R&D News | pharmaphorum

News

GSK plans $800m US manufacturing investment

GSK has made another investment in its manufacturing network, setting aside $800 million to build two plants at its Marietta site in the US.

News

MSD buys Modifi for $1.3bn to boost oncology pipeline

MSD has acquired Yale University spinout Modifi Biosciences, claiming ownership of a potential new class of therapeutics for difficult-to-treat brain tumours, including glioblastomas.

News

Intellia trumpets CRISPR drug data, but shares fall

Intellia has reported results from a phase 2 trial of its gene-editing drug for hereditary angioedema (HAE) that it says build the case for the drug as a phase 3 trial gets underway – but i

News

WhatsApp lands Moderna in hot water with PMCPA

A WhatsApp message has earned Moderna a reprimand from the UK's Prescription Medicines Code of Practice Authority (PMCPA), with Novo Nordisk, Otsuka, AstraZeneca, and Daiichi Sankyo also fo

News

Lundbeck president and CEO Charl van Zyl

Lundbeck planning for four novel drugs in phase 3 in 2026

Denmark's Lundbeck has said that efforts to build its R&D portfolio are on track to deliver four new molecular entities (NMEs) in phase 3 trials in 2026, including an epilepsy drug from

News

implantable hormone biosensor from Impli

Bayer partners medtech firm Impli on fertility R&D

Bayer has entered into an alliance with Impli, tapping into the start-up's implantable hormone-monitoring platform, which has potential in fertility treatment and other indications.

GSK plans $800m US manufacturing investment

MSD buys Modifi for $1.3bn to boost oncology pipeline

Intellia trumpets CRISPR drug data, but shares fall

WhatsApp lands Moderna in hot water with PMCPA

Lundbeck planning for four novel drugs in phase 3 in 2026

Bayer partners medtech firm Impli on fertility R&D

Madrigal builds in MASH with $4.4bn+ Ribo alliance

How to meet your physicians where they are online

News

Editor's Picks